Resources

In this guest blog, Asma Aslam says that rising domestic costs and strong overseas capabilities are pushing companies to subcontract abroad.

Stratosvir has received support from Cell and Gene Therapy Catapult (CGT Catapult), including investment from the Cross Catapult Investment Pilot.

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

UK biotech financing showed signs of recovery in the first quarter of 2026, driven by a rebound in venture capital investment.

In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.

Epitopea announced that it has received approval from MHRA and the REC for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of CryptiVax™-1001.

Coulter Partners successfully led a search assignment for Oral Care AB and is pleased to announce the placement of Lucas Kromann as Chief Executive Officer (CEO) Denmark.

The UK BioIndustry Association (BIA) is the UK’s trade association for innovative life sciences and the leading UK-wide forum for expert communities and high quality peer-to-peer networking in the sector.

In this blog, Ethan Almond reflects on the successes and innovative technology of biosolutions company and BIA member twig.

The UK’s biosolutions sector has established itself as a billion-pound frontier industry, with companies raising £1.46 billion in equity investment since 2018.

In this guest blog, Lee Smith and Spiros Servos argue that early-stage biotech leaders who secure investment in 2026 are those who integrate commercial thinking early, aligning science, clinical strategy and market realities into a credible narrative for investors.

Coulter Partners successfully led a search for Babraham Research Campus Ltd (BRCL) and is pleased to announce the placement of Dr. Rich Ferrie as Chief Executive Officer (CEO).

Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, has appointed Edwin Moses as Chair of the Board of Directors, with immediate effect.

Some of the UK’s most ambitious early-stage life science companies are choosing Victoria House as their London base, adding fresh momentum to one of the capital’s most exciting life science communities.

PrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in 2026.

International contract research organisation ChemPartner has officially opened its first European scientific hub at Discovery Park, Sandwich, Kent.

The UK Medicines and Healthcare products Regulatory Agency has granted Clinical Trial Authorisation for the POLB 001 TOPICAL trial.

In this guest blog, Dan Stanton, Trade Media Expert at Sartorius Bioprocess Solutions, discusses how tight funding, manual tech transfer and product specific analytics are keeping cell and gene therapies (CGTs) from realising their potential.